10-Q: InMed Pharma Faces Regulatory Headwinds, Going Concern Doubt

InMed Pharmaceuticals reported a reduced net loss and increased cash, but faces significant uncertainty from new U.S. legislation impacting its BayMedica subsidiary and ongoing legal disputes, alongside a stated going concern doubt.

Summary

• Net loss decreased to $3.8 million for the six months ended December 31, 2025, from $4.3 million in the prior year.
• Cash and cash equivalents increased to $7.0 million as of December 31, 2025, from $3.4 million a year prior.
• Sales in the Commercial segment (BayMedica) decreased by 18% to $1.94 million for the six months, primarily due to uncertainty from new U.S. legislation (H.R. 5371) and lower sales prices.
• The company has identified substantial doubt about its ability to continue as a going concern within one year.
• Successful completion of pharmacokinetic studies for Alzheimer's drug candidate INM-901 in large animal models.
• Phase 2 clinical trial for INM-755 (Epidermolysis Bullosa) showed positive anti-itch activity.
• BayMedica is involved in an arbitration with a licensor seeking approximately $3.4 million in past payments and $2.3 million annually for the remainder of the agreement term, with an amended claim for unspecified damages.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the explicit 'going concern' doubt, significant revenue decline in the commercial segment, and the material threat posed by potential U.S. legislation to BayMedica's core business, despite some R&D progress.

Positives

• Net loss for the six months ended December 31, 2025, decreased to $3.8 million from $4.3 million in the prior year, representing a 12% improvement.
• Cash and cash equivalents increased significantly to $6.95 million as of December 31, 2025, compared to $3.42 million as of December 31, 2024.
• Research and development expenses in the Pharma segment decreased by 24% ($0.4 million) for the six months ended December 31, 2025, compared to the prior year.
• Successful completion of pharmacokinetic studies for INM-901 (Alzheimer's disease candidate) in large animal models, guiding human Phase 1 clinical trial design.
• Completed chemistry, manufacturing, and controls development to scale INM-901 manufacturing for Investigational New Drug (IND) enabling studies.
• Phase 2 clinical trial of INM-755 (Epidermolysis Bullosa) cream showed a positive indication of enhanced anti-itch activity.
• Ocular research for INM-089 (dry Age-Related Macular Degeneration) indicates potentially promising neuroprotective effects.

Negatives

• Sales in the Commercial segment (BayMedica) decreased by 18% to $1.94 million for the six months ended December 31, 2025, compared to $2.38 million in the prior year.
• Gross profit decreased by 38% to $587,353 for the six months ended December 31, 2025, from $954,307 in the prior year.
• The Commercial segment shifted from a net income of $396,000 in the six months ended December 31, 2024, to a net loss of $17,000 in the same period of 2025.
• An inventory write-down of $70,000 was recorded during the six months ended December 31, 2025, due to net realizable value.
• Accumulated deficit increased to $121.0 million as of December 31, 2025, from $117.2 million as of June 30, 2025.
• Total assets decreased to $11.19 million as of December 31, 2025, from $15.58 million as of June 30, 2025.
• Total shareholders' equity decreased to $9.59 million as of December 31, 2025, from $13.43 million as of June 30, 2025.

Risks

• Substantial doubt about the ability to continue as a going concern within one year due to recurring losses and negative cash flows.
• Material negative impact on BayMedica's commercial business and inventory of rare, non-intoxicating cannabinoids if U.S. congressional legislation H.R. 5371 comes into force on November 12, 2026, in its current form.
• Potential need to write-off inventory, divest BayMedica's commercial business, pivot manufacturing techniques, or discontinue the business if H.R. 5371 is enacted without changes.
• Ongoing arbitration (Patent License Matter) with a third-party licensor seeking approximately $3.4 million in past annual payments (2022-2024) and $2.3 million in guaranteed annual minimum payments for the remainder of the agreement term, plus unspecified damages for alleged breaches. An unfavorable outcome would have a material adverse impact.
• Inability to obtain additional financing on acceptable terms or at all, which may adversely affect existing shareholders.
• Uncertainty regarding the nature, timing, and estimated costs to complete development and commercialization of Product Candidates.
• Risks associated with the timing and progress of preclinical and clinical development activities, regulatory approvals, manufacturing, intellectual property protection, and market acceptance.
• Potential for dilution of ownership interests if additional capital is raised through equity financings.
• Covenants in debt securities could restrict operations if debt financing is pursued.
• Relinquishing valuable rights to technologies, future revenue streams, or Product Candidates if funds are raised through collaboration arrangements.

Future Outlook

The company expects its cash, cash equivalents, and short-term investments of approximately $7.0 million as of December 31, 2025, to fund operating expenses and capital expenditure requirements into the fourth quarter of calendar 2026, contingent on BayMedica revenues and operating expenses. Research and development expenses are expected to increase significantly in future periods as the company continues to implement its business strategy. General and administrative expenses are anticipated to remain consistent. The future viability is dependent on raising additional capital, which may not be available on acceptable terms. BayMedica is evaluating alternative options for its commercial business due to potential prohibitive U.S. legislation, including divestiture, pivoting manufacturing, or discontinuing the business.

Management Comments

• We expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy.
• We anticipate general and administrative expenses to remain consistent in future periods.
• The Commercial segment will continue to evaluate opportunities for potential structured supply arrangements and collaborations for the commercial business.
• Sales and marketing efforts will remain focused on products that contribute the highest margins, where the Commercial segment continues to hold a strong competitive position.
• We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.
• We expect to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions.
• BayMedica is evaluating alternative options but has not set a timetable for the conclusion of its evaluation, nor has it made any definitive decisions related to any potential alternative options at this time.
• BayMedica is continuing to sell its inventory of rare, non-intoxicating cannabinoids.
• Without timely, meaningful changes to the Act, we would need to write-off any inventory that BayMedica is unable to sell prior to the Act becoming effective and take other actions, which could include divesting BayMedicas commercial business, if possible, pivoting to other manufacturing techniques, if commercially viable, or discontinuing BayMedicas commercial business, all of which would have a material adverse effect on our business, results of operations and financial condition.
• BayMedica vehemently contests the Licensors interpretation of the Agreement and its position in the Patent License Matter, and intends to take all necessary steps to vigorously defend the Patent License Matter.

Industry Context

StockSavvy.ai notes that InMed Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical sector, where R&D success is uncertain and regulatory hurdles are significant. The challenges faced by its BayMedica subsidiary due to potential U.S. legislation (H.R. 5371) highlight the evolving and often unpredictable regulatory landscape for cannabinoid products, which could impact other companies in the health and wellness cannabinoid market. The company's focus on rare cannabinoids and proprietary manufacturing (IntegraSyn) aims to differentiate it, but the commercial viability is now directly threatened by legislative changes. The ongoing legal dispute with a licensor also underscores the complexities of intellectual property and licensing agreements common in the biotech industry.

Comparison to Industry Standards

• The company's recurring losses and "substantial doubt about its ability to continue as a going concern" are below industry standards for established pharmaceutical companies, which typically demonstrate profitability or a clear path to commercialization with sufficient funding.
• The 18% decline in commercial sales, coupled with an inventory write-down, suggests underperformance compared to growth expectations in the broader health and wellness cannabinoid market, which, despite regulatory uncertainties, has seen significant expansion in other segments.
• The progress in preclinical and Phase 2 clinical trials (INM-901 for Alzheimer's, INM-755 for EB) is consistent with the typical long development timelines in the pharmaceutical industry, but the lack of a clear partnership for INM-755 after Phase 2 completion indicates potential challenges in securing external funding or commercialization pathways, which successful peers often achieve earlier.
• The legal dispute over royalty payments and alleged breaches of a technology license agreement is a specific company issue, but intellectual property disputes are common in the biotech sector, where companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) have successfully navigated complex patent landscapes for cannabinoid-based drugs.

Corporate Governance

Legal Proceedings

• BayMedica is involved in an arbitration (Patent License Matter) with a third-party licensor who claims approximately $3.4 million in past annual royalty payments (2022-2024) and a declaration that BayMedica is liable for approximately $2.3 million in guaranteed annual minimum payments for the remainder of the agreement term.
• BayMedica vehemently disputes the licensor's interpretation of the agreement and has filed a Response to Notice of Arbitration and a Notice of Motion seeking summary dismissal, arguing the claims are statute-barred.
• On January 16, 2026, the licensor delivered an Amended Notice of Arbitration alleging BayMedica breached several obligations, including failing to ensure sublicensee compliance with reporting and remitting required royalties, seeking unspecified damages and specific performance.
• An unfavorable outcome in this matter would have a material adverse impact on BayMedica's business and financial condition and its ability to continue operations.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings (SEPA, other capital raises) and adverse impact on share value due to going concern doubt, declining commercial sales, and legal/regulatory risks.
• Employees: Uncertainty regarding BayMedica's future operations due to potential legislation could impact job security in that segment. Continued R&D efforts in Pharma segment may offer stability for those employees.
• Customers (BayMedica): Uncertainty around the synthetic cannabinoid market due to H.R. 5371 could disrupt supply or availability of products, potentially leading to a loss of customers if BayMedica's business is discontinued or significantly altered.
• Suppliers: Potential impact on relationships if BayMedica's operations are curtailed or discontinued, affecting demand for raw materials or services.
• Creditors: Increased risk due to the "going concern" doubt and the company's reliance on future capital raises.

Next Steps

• Raise additional capital through equity financings, debt financings, collaborations, government contracts, or other strategic transactions.
• Continue research and development activities for Product Candidates, with expected increases in R&D expenses.
• Continue to scale the INM-901 manufacturing process in preparation for Investigational New Drug (IND) enabling studies and regulatory interaction with the FDA.
• Pursue strategic partnership opportunities for INM-755 in Epidermolysis Bullosa and other itch-related skin conditions.
• BayMedica to continue evaluating alternative options for its commercial business in response to potential U.S. legislation (H.R. 5371), including divestiture, pivoting manufacturing, or discontinuing the business.
• BayMedica to continue selling its inventory of rare, non-intoxicating cannabinoids.
• Vigorously defend the Patent License Matter arbitration, with a motion for summary dismissal scheduled for May 6, 2026.
• Assess the impact of adopting new accounting standards (ASU 2025-12, ASU 2025-11, ASU 2025-05).

Key Dates

Recommendation

The company explicitly states 'substantial doubt about its ability to continue as a going concern' within one year, which is a critical red flag for investors. This, combined with a significant decline in commercial segment sales and gross profit, and the material threat of U.S. legislation potentially prohibiting BayMedica's core business, points to severe operational and financial instability. The ongoing legal dispute with a licensor seeking millions in payments further exacerbates the risk profile. While there is some R&D progress, the overall financial health and immediate future prospects are highly precarious, making the stock a strong sell for seasoned investors.

Keywords

InMed Pharmaceuticals, INM, 10-Q, Quarterly Report, Biotechnology, Pharmaceuticals, Cannabinoids, BayMedica, Alzheimer's Disease, Epidermolysis Bullosa, Dry AMD, Drug Development, Clinical Trials, Going Concern, SEC Filing, Biopharma, Rare Cannabinoids, IntegraSyn, INM-901, INM-755, INM-089, H.R. 5371, Regulatory Risk, Arbitration, Patent License Matter, Capital Raise